Results 231 to 240 of about 82,941 (302)

Konjac petroleum ether extract inhibits triple-negative breast cancer cell migration and invasion by attenuating <i>OLFML2A</i>-mediated epithelial-mesenchymal transition. [PDF]

Front Pharmacol
Chen Y, Yu Q, Ding H, Jiang W, Gao X.
europepmc   +1 more source

Safety and Efficacy of HexaBody‐DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT HexaBody‐DR5/DR5 (GEN1029) is a death receptor 5 (DR5) agonist composed of two humanized immunoglobulin G1 (IgG1) antibodies, Hx‐DR5‐01 and Hx‐DR5‐05, that bind non‐overlapping DR5 epitopes with nanomolar affinity. HexaBody‐DR5/DR5 is designed to activate the TRAIL pathway through DR5 clustering. This phase 1/2a, open‐label, multi‐center study
Marije B. Overdijk, Kristin Strumane, Ruth Plummer, Patricia LoRusso, Jordi Rodon Ahnert, Udai Banerji, Elena Garralda, Emiliano Calvo, Han Si, Naomi Hoevenaars, Jens Thing Mortensen, Sieto Bosgra, Anders Malmberg, Merete Ellekilde‐Pedersen, Teresa Ramirez‐Andersen, Panagiota Diamantopoulou Reiter, Elena Favaro, Ulf Forssmann, Esther C. W. Breij, Maria Jure‐Kunkel   +19 more
wiley   +1 more source

Endoplasmic Reticulum-Targeting NIR Cyanine ER800 Nanoparticles Promote Pyroptosis in Triple-Negative Breast Cancer. [PDF]

ACS Appl Mater Interfaces
Yang J, Jiang J, Yang Y, Shen Z, Lin Z, Gao X, Wu W, Ye Z, Gao J, Gao N.   +9 more
europepmc   +1 more source

Real‐world prevalence of PD‐L1 positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study

Histopathology, Volume 88, Issue 7, Page 1373-1384, June 2026.
In the real‐world VANESSA study in triple‐negative breast cancer, PD‐L1‐positive prevalence was 38% in early‐stage and 20% in metastatic tumours, lower than in prospective trials. The lower prevalence in smaller versus larger tissue samples and by local versus central assessment underlines the importance of robust PD‐L1 testing to determine eligibility
Corrado D'Arrigo, Sitki Tuzlali, Romualdo Barroso‐Sousa, Nagi S El Saghir, Rebecca Dent, Nataša Medić‐Milijić, Gyungyub Gong, Shahin Sayed, Tu Thai Anh, Alisan Zirtiloglu, Götz Hartleben, Paula Toro, Iman Estaytieh, Enya Weber, Regula Deurloo, João Mouta, Lazar Popovic   +16 more
wiley   +1 more source

Social disparities in the frequency and severity of triple-negative breast cancer at diagnosis in a university hospital in Paris, France: confronting race and ethnic blindness. [PDF]

PLoS One
Chauvin P, Huet T, Gligorov J, Sargent C.   +3 more
europepmc   +1 more source

Immunotherapy in TNBC

openaire   +1 more source

Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple‐Negative Breast Cancer

Journal of Cellular and Molecular Medicine, Volume 30, Issue 11, June 2026.
ABSTRACT This study aimed to elucidate the mechanism of action of Schisandrin A in the intervention of triple‐negative breast cancer (TNBC). Through the application of network pharmacology and the integration of targets from multiple databases, the research identified 128 overlapping targets between Schisandrin A and TNBC.
Meng Xu, Yingchun Zhang, Rubing Mei, Tingting Xue, Hongning Cai, Yu Zhou, Jianfang Guo   +6 more
wiley   +1 more source

m6A-modified circFOXA1 promotes tumor immune evasion via enhancing PD-L1 deubiquitination in triple-negative breast cancer. [PDF]

Cytotechnology
Shen H, Li B, Wen X, Zhao C, Wang C.
europepmc   +1 more source

Effect of the Mutual Interaction of GPNMB and LPAR1 on Cellular Motility and Tumorigenicity in Mammary Epithelial Cells

Pathology International, Volume 76, Issue 6, June 2026.
GPNMB and LPAR1 form a positive feedback loop enhancing LPA signaling. LPA–LPAR1 activates RhoA–ROCK, driving actin reorganization and cell motility. GPNMB–LPAR1 signaling promotes tumorigenic potential. ABSTRACT Glycoprotein non‐metastatic melanoma protein B (GPNMB) is a poor prognostic factor, which is highly expressed in many types of malignant ...
Minori Kimura, Yukari Okita, Erina Iwabuchi, Xinzhu Hong, Yumu Ichikawa, Manar A. Elhinnawi, Hironobu Sasano, Mitsuyasu Kato   +7 more
wiley   +1 more source